Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003Astri Fjelde Maaland, Jostein Dahle, Amal Saidi et al.|PLoS ONE|2020Cited by 39
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003Astri Fjelde Maaland, Jostein Dahle, Helèn Heyerdahl et al.|European Journal of Nuclear Medicine and Molecular Imaging|2019Cited by 16
Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)Amal Saidi, Jostein Dahle, Helèn Heyerdahl et al.|Blood|2018Cited by 5
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitroMarion Masitsa Malenge, Jostein Dahle, Astri Fjelde Maaland et al.|PLoS ONE|2022Cited by 3
The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid LeukaemiaTara Helen Dowling Dowling Steinsland, Emmet McCormack, Stein‐Erik Gullaksen et al.|Blood|2020Cited by 1